Suggested Guidelines for Patient Monitoring: Hepatic and Hematologic Toxicity Attributable to Systemic Dermatologic Drugs

Dermatologic Clinics

Volumn 25, Issue 2, 2007, Pages 195-205

  Wolverton, Stephen E ^a   Remlinger, Kathleen ^b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; AZATHIOPRINE; CHLORAMBUCIL; CHLOROQUINE; CIMETIDINE; COLCHICINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ERYTHROMYCIN; ERYTHROMYCIN ESTOLATE; ETRETIN; FLUCONAZOLE; FOLIC ACID; FOLINIC ACID; HYDROXYCHLOROQUINE; ITRACONAZOLE; KETOCONAZOLE; METHOTREXATE; MINOCYCLINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PENICILLIN G; PRIMAQUINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETINOID; SALAZOSULFAPYRIDINE; SULFONAMIDE; UNINDEXED DRUG;

AGRANULOCYTOSIS; ANEMIA; APLASIA; APLASTIC ANEMIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CYTOPENIA; DIFFERENTIAL DIAGNOSIS; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; FATTY LIVER; HEMOLYSIS; HEMOLYTIC ANEMIA; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; METHEMOGLOBINEMIA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PANCYTOPENIA; PATHOGENESIS; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; PSORIASIS; REVIEW; RISK FACTOR; STEATOSIS; THROMBOCYTOPENIA; VIRUS HEPATITIS;

DERMATOLOGIC AGENTS; DRUG MONITORING; HEMATOLOGIC DISEASES; HUMANS; LIVER; LIVER DISEASES; PRACTICE GUIDELINES; SKIN DISEASES;

EID: 34147108604     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.det.2007.02.001     Document Type: Review

References (66)

1. Zimmerman H.J., and Ishak K.G. General aspects of drug-induced liver disease. Gastroenterol Clin North Am 24 (1995) 739-757
2. Lee W.M. Medical progress: drug-induced hepatotoxicity. N Engl J Med 349 (2003) 474-485
3. O'Grady J.G., Alexander G.J., Hayllar K.M., et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97 (1989) 439-445
4. Walgren J.L., Mitchell M.D., and Thompson D.C. Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit Rev Toxicol 35 (2005) 325-361
5. Fontana R.J., and Watkins P.B. Genetic predisposition to drug-induced liver disease. Gastroenterol Clin North Am 24 (1995) 811-837
6. Pessayre D. Role of reactive metabolites in drug-induced hepatitis. J Hepatol 23 Suppl 1 (1995) 16-24
7. Van Pelt F.N., Straub P., and Manns M.P. Molecular basis of drug-induced immunological liver injury. Semin Liver Dis 15 (1995) 283-300
8. Robin M.A., LeRoy M., Descatoire V., et al. Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J Hepatol 26 Suppl 1 (1997) 23-30
9. Beaune P.H., and Bourdi M. Autoantibodies against cytochromes P-450 in drug-induced autoimmune hepatitis. Ann N Y Acad Sci 685 (1993) 641-645
10. Seeff L.B., Cuccherini B.A., Zimmerman H.J., et al. Acetaminophen hepatotoxicity in alcoholics: a therapeutic misadventure. Ann Intern Med 104 (1986) 399-404
11. Lee W.M. Medical progress: drug-induced hepatotoxicity. N Engl J Med 333 (1995) 1118-1127
12. Garibaldi R.A., Drusin R.E., Ferebee S.H., et al. Isoniazid-associated hepatitis: report of an outbreak. Am Rev Respir Dis 106 (1972) 357-365
13. Roenigk Jr. H.H., Auerbach R., Maibach H.I., et al. Methotrexate in psoriasis: consensus conference. J Am Acad Dermatol 38 (1998) 478-485
14. Wolverton S.E. Major adverse effects from systemic drugs: defining the risks. Curr Probl Dermatol 7 (1995) 1-40
15. Vahlquist A. Long-term safety of retinoid therapy. J Am Acad Dermatol 27 (1992) S29-S33
16. Knowles S.R., Gupta A.K., Shear N.H., et al. Azathioprine hypersensitivity-like reactions-a case report and a review of the literature. Clin Exp Dermatol 20 (1995) 353-356
17. Prussick R., and Shear N.H. Dapsone hypersensitivity syndrome. J Am Acad Dermatol 35 (1996) 346-349
18. Lawrence W.A., Olsen H.W., and Nickles D.J. Dapsone hepatitis. Arch Intern Med 147 (1987) 175
19. Elkayam O., Yaron M., and Caspi D. Minocycline-induced autoimmune syndromes: an overview. Semin Arthritis Rheum 28 (1999) 392-397
20. Knowles S., Shapiro L., and Shear N. Serious adverse reactions induced by minocycline: a report of 13 patients and review of the literature. Arch Dermatol 132 (1996) 934-939
21. Tygstrup N. Assessment of liver function: principles and practice. J Gastroenterol Hepatol 5 (1990) 468-482
22. Sallie R., Tredger J.M., and Williams R. Drugs and the liver. Part 1: testing liver function. Biopharm Drug Dispos 12 (1991) 251-259
23. Giannini E.G., Testa R., and Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 172 (2005) 367-379
24. In: Wolverton S.E. (Ed). Comprehensive dermatologic drug therapy. 2nd edition (2007), Elsevier, London
25. Knowles S.R., and Shear N.H. Cutaneous drug reactions with systemic features. In: Wolverton S.E. (Ed). Comprehensive dermatologic drug therapy. 2nd edition (2007), Elsevier, London 977-988
26. Callen J.P., Kulp-Shorten C.L., and Wolverton S.E. Methotrexate. In: Wolverton S.E. (Ed). Comprehensive dermatologic drug therapy. 2nd edition (2007), Elsevier, London 163-181
27. Verweij J., Sparreboom A., and Nooter K. Antitumor antiobiotics. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy. 3rd edition (2001), Lippincott Williams & Wilkins, Philadelphia 490
28. Remlinger K.A. Hematologic toxicity of drug therapy. In: Wolverton S.E. (Ed). Comprehensive dermatologic drug therapy. 2nd edition (2007), Elsevier, London 893-909
29. van Staa T.P., Boulton F., Cooper C., et al. Neutropenia and agranulocytosis in England and Wales: incidence and risk factors. Am J Hematol 72 (2003) 248-254
30. van der Klauw M.M., Wilson J.H.P., and Stricker B.H.C. Drug-associated agranulocytosis: 20 years of reporting in the Netherlands (1974-1994). Am J Hematol 57 (1998) 206-211
31. Ibanez L., Vidal X., Ballarin E., et al. Population-based drug-induced agranulocytosis. Arch Intern Med 165 (2005) 869-874
32. van der Klauw M.M., Goudsmit R., Halie R., et al. A population-based case-cohort study of drug-associated agranulocytosis. Arch Intern Med 159 (1999) 369-374
33. Rawson N.B., Harding S.R., Malcolm E., et al. Hospitalizations for aplastic anemia and agranulocytosis in Saskatchewan: incidence and associations with antecedent prescription drug use. J Clin Epidemiol 12 (1998) 1345-1355
34. Wiholm B.-E., and Emanuelsson S. Drug-related blood dyscrasias in a Swedish reporting system, 1985-1994. Eur J Haematol 57 Suppl (1996) 42-46
35. Kaufman D.W., Kelly J.P., Jurgelon J.M., et al. Drugs in the aetiology of agranulocytosis and aplastic anaemia. Eur J Haematol 57 Suppl (1996) 23-30
36. Baumelou E., Guiguet M., Mary J.Y., et al. Epidemiology of aplastic anemia in France: a case control study. I. Medical history and medication use. Blood 81 (1993) 1471-1478
37. Standardization of definitions and criteria of causality assessment of adverse drug reactions. Drug-induced cytopenia. Int J Clin Pharmacol Ther Toxicol 29 (1991) 75-81
38. George J.N., Raskob G.E., Shah S.R., et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 129 (1998) 886-890
39. Duhra P. Treatment of gastrointestinal symptoms associated with methotrexate therapy for psoriasis. J Am Acad Dermatol 28 (1993) 466-469
40. Silvis N.G. Antimetabolites and cytotoxic drugs. Dermatol Clin 19 (2001) 105-118
41. Weinblatt M.E., and Fraser P. Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 32 (1989) 1592-1596
42. Andersen W.K., and Feingold D.S. Adverse drug interactions clinically important for the dermatologist. Arch Dermatol 131 (1995) 468-473
43. Anstey A. Azathioprine in dermatology: a review in light of advances in understanding methylation pharmacogenetics. J R Soc Med 88 Suppl (1995) 155P-160P
44. Anstey A.V., Wakelin S., and Reynolds N.J. Guidelines for prescribing azathioprine in dermatology. Br J Dermatol 151 (2004) 1123-1132
45. Hande K.R. Purine antimetabolites. In: Chabner B.A., and Longo D.L. (Eds). Cancer chemotherapy and biotherapy. 3rd edition (2001), Lippincott Williams & Wilkins, Philadelphia 295-308
46. Coleman M.D. Dapsone-mediated agranulocytosis: risks, possible mechanisms and prevention. Toxicology 162 (2001) 53-60
47. Gregg X.T., Prchal J.T., et al. Red blood cells: enzymopathies of glutathione metabolism. In: Hoffman R., Benz E.J., and Shattil S.J. (Eds). Hematology: basic principles and practice. 4th edition (2004), Elsevier, Philadelphia 657-660
48. Keisu M., Wiholm B.-E., and Palmblad J. Trimethoprim-sulphamethoxazole-associated blood dyscrasias. Ten years' experience of the Swedish spontaneous reporting system. J Intern Med 228 (1990) 353-360
49. Mary J.Y., Guiget M., Baumelou E., et al. Drug use and aplastic anaemia: the French experience. Eur J Haematol 57 Suppl (1996) 35-41
50. Anttila P.M., Valimaki M., and Pentikainen P.J. Pure-red-cell aplasia associated with sulphasalazine but not 5-aminosalicylic acid. [letter]. Lancet 2 (1985) 1006
51. Herbert V. Metabolism of folic acid in man. J Infect Dis 128 Suppl (1973) S601-S606
52. Grove M.L., Hassell A.B., Hay E.M., et al. Adverse reactions to disease-modifying anti-rheumatic drugs in clinical practice. QJM 94 (2001) 309-319
53. Beutler E. The hemolytic effect of primaquine and related compounds: a review. Blood 14 (1959) 103-139
54. Ben-Chetrit E., and Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 28 (1998) 48-59
55. Dixon A.J., and Wall G.C. Probable colchicine-induced neutropenia not related to intentional overdose. Ann Pharmacother 35 (2001) 192-195
56. Ferrannini E., and Pentimone F. Marrow aplasia following colchicine treatment for gouty arthritis. Clin Exp Rheumatol 2 (1984) 173-175
57. Ducloux D., Schuller V., and Chalopin J.-M. Colchicine agranulocytosis. [letter]. Nephrol Dial Transplant 12 (1997) 1541-1542
58. Grundmann-Kollmann M., Korting H.C., Behrens S., et al. Mycophenolate mofetil: a new therapeutic option in the treatment of blistering autoimmune diseases. J Am Acad Dermatol 40 (1999) 957-960
59. Enk A.H., and Knop J. Mycophenolate is effective in the treatment of pemphigus vulgaris. Arch Dermatol 135 (1999) 54-56
60. Raptiva® (efalizumab) [package insert] (2003), Genentech, South San Francisco (CA)
61. Favalli E.G., Varenna M., and Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin Exp Rheumatol 23 (2005) 247-250
62. Windhorst D.B., and Nigra T. General clinical toxicology of oral retinoids. J Am Acad Dermatol 6 (1982) 675-682
63. Kovacs M.J., Alshammari S., Guenther L., et al. Neutropenia and pancytopenia associated with oral terbinafine. [letter]. J Am Acad Dermatol 31 (1994) 806
64. Gupta A.K., Soori G.S., Del Rosso J.Q., et al. Severe neutropenia associated with oral terbinafine therapy. J Am Acad Dermatol 38 (1998) 765-767
65. Ornstein D.L., and Ely P. Reversible agranulocytosis associated with oral terbinafine for onychomycosis. J Am Acad Dermatol 39 (1998) 1023-1024
66. Salama A., and Mueller-Eckhardt C. Immune-mediated blood cell dyscrasias related to drugs. Semin Hematol 29 (1992) 54-63